PDCD1LG2 and hepatocellular carcinoma: Three subtypes of IPS values (IPS-CTLA4, IPS-PD-1/PD-L1/PD-L2, and IPS-CTLA4/PD-1/PD-L1/PD-L2) were selected to assess the response of HCC patients to anti-PD-1/PD-L1/PD-L2 therapy, anti-CTLA4 therapy, or anti- PD-1/PD-L1/PD-L2 and anti-CTLA4 combination therapy.